Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Megestrol
Drug ID BADD_D01371
Description 17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Indications and Usage For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.
Marketing Status Not Available
ATC Code G03AC05; G03DB02; L02AB01
DrugBank ID DB00351
KEGG ID D08167
MeSH ID D008535
PubChem ID 19090
TTD Drug ID D04GJN
NDC Product Code 46439-8722; 68094-250; 0555-0607; 17856-0907; 49884-230; 49884-907; 50383-859; 63629-2220; 63739-549; 64380-158; 66689-020; 81646-120; 51991-313; 77044-5047; 0121-4776; 49884-290; 63629-7631; 71205-943; 0009-5030; 24979-041; 60429-433; 63629-2221; 0555-0606; 43744-363; 51927-1670; 63592-0109; 0904-3571; 49884-289; 63629-2219; 0904-7072; 0121-0945; 60432-126; 64380-159; 68094-361; 72969-102; 55154-5776
Synonyms Megestrol | 17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione | Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-
Chemical Information
Molecular Formula C22H30O3
CAS Registry Number 3562-63-8
SMILES CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pollakiuria20.02.02.007--
Pregnancy18.08.02.004--Not Available
Pruritus23.03.12.001--
Pulmonary embolism22.06.02.001; 24.01.06.001--Not Available
Rash23.03.13.001--Not Available
Rash pustular23.03.10.003; 11.01.12.002--
Salivary hypersecretion07.06.01.009--Not Available
Seizure17.12.03.001--
Skin disorder23.03.03.007--Not Available
Thinking abnormal17.02.05.023; 19.10.03.001--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tumour flare16.32.03.001--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary tract infection20.08.02.001; 11.01.14.004--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Deep vein thrombosis24.01.02.003--Not Available
Affect lability19.04.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Embolism24.01.01.009--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Candida infection11.03.03.021--
The 3th Page    First    Pre   3    Total 3 Pages